Medical News Today: Topical drug leads to complete remission for some patients with rare skin lymphoma

Researchers reveal how a topical drug called resiquimod led to total remission for some patients with a cutaneous T cell lymphoma - a rare skin lymphoma.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news

Related Links:

ConclusionThe reason for the association between the high serum copper levels and adverse prognosis is unknown. We hypothesized that interleukin-6 is secreted primarily by non-neoplastic cells at MF skin sites, leading to release of copper by the liver. Local production of interleukin-6 at the lesion sites might conceivably also promote neoplastic cell progression by stimulation of the STAT3 pathway. Further studies on the relationship between activated tumor-associated macrophages, serum copper levels, interleukin-6, or C-reactive protein and prognosis might be informative.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
ConclusionThe reason for the association between high serum copper and adverse prognosis is unknown. We hypothesize that IL-6 is secreted primarily by non-neoplastic cells at MF skin sites, leading to release of copper by the liver. Local production of IL-6 at lesion sites conceivably might also promote neoplastic cell progression via stimulation of the STAT3 pathway. Further studies on the relationship between activated tumor-associated macrophages, serum copper, IL-6 or C-reactive protein and prognosis might be informative.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Greater than normal serum copper levels in a subset of patients with early mycosis fungoides lymphoma correlated with a worse prognosis compared with that of patients with normal copper levels. The reason for this association is unknown. We hypothesized that inflammatory cytokines such as interleukin-6 secreted by inflammatory cells in skin lesions might play a role in disease progression.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
An above normal serum copper level in a subset of patients with early mycosis fungoides lymphoma correlated with a worse prognosis compared to patients with normal copper levels. The reason for this association is unknown. We hypothesize that inflammatory cytokines such as interleukin-6 secreted by inflammatory cells in skin lesions may play a role in disease progression.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Conclusion. Due to the good toxicity profile and the oral administration, combined therapy with momelotinib and citarinostat may represent a promising novel therapeutic modality for hematological malignancies. The study is ongoing and further investigation is required.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - Category: Hematology Authors: Tags: 802. Chemical Biology and Experimental Therapeutics: Poster II Source Type: research
Acetylation is a reversible process under the control of histone acetyltransferases (HATs) and histone deacetylases (HDACs). Acetyl proteome analysis revealed that acetylation regulates various cellular processes through both histone and non-histone proteins (Choudhary et al., Science, 2008). Subsets of diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) have inactivating mutations of HATs, CBP and p300 (Pasqualucci et al., Nature, 2011). In addition, p300 mutation is a poor prognostic factor in FL patients (Pastore et al., Lancet Oncol, 2015). In a mouse model, CBP deficiency promotes B cell lymphomagenesis...
Source: Blood - Category: Hematology Authors: Tags: 622. Lymphoma Biology-Non-Genetic Studies: Poster I Source Type: research
ConclusionBexarotene monotherapy is well-tolerated and has encouraging activity in PTCL that warrants further investigation. This agent should be considered for further prospective trials in this setting.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
In this report we present a patient with SPLTCL, who has been successfully treated with mycophenolate mofetil (MMF).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
In this report we present a patient with subcutaneous panniculitis-like T-cell lymphoma, who has been successfully treated with mycophenolate mofetil.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Publication date: Available online 27 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Francine M. Foss, Terri L. Parker, Michael Girardi, Anlong LiSummaryCutaneous T-cell lymphomas (CTCL) are rare, heterogeneous non-Hodgkin lymphomas with poor prognoses. Treatment options for CTCL are limited by the their efficacy and tolerability profile. Pralatrexate has demonstrated efficacy in T-cell lymphomas, however dose-modifying adverse events, such as mucositis have occurred. We retrospectively reviewed clinical responses and toxicity in 27 CTCL patients treated with pralatrexate at doses ranging from 10-30mg/...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cutaneous T cell lymphoma | Health | Leukemia | Lymphoma | Myeloma | Skin | T-cell Lymphoma